Clinical-anamnestic analysis of patients diagnosed as "Anaphylaxis" hospitalized in Moscow medical hospitals
- Authors: Nikitina E.A.1, Lebedkina M.S.1, Mukhina O.A.1, Andreev S.S.1, Chernov A.A.1, Chicunov N.S.2, Klimanova Y.M.3, Porfireva S.М.3, Lysenko M.A.1,4, Fomina D.S.1,3,5
-
Affiliations:
- Moscow City Hospital 52
- Moscow Center for Innovative Technologies in Healthcare
- The First Sechenov Moscow State Medical University (Sechenov University)
- The Russian National Research Medical University named after N.I. Pirogov
- Astana Medical University
- Issue: Vol 21, No 1 (2024)
- Pages: 82-97
- Section: Original studies
- Submitted: 20.12.2023
- Accepted: 21.03.2024
- Published: 15.04.2024
- URL: https://rusalljournal.ru/raj/article/view/16909
- DOI: https://doi.org/10.36691/RJA16909
- ID: 16909
Cite item
Abstract
BACKGROUND: Anaphylaxis is a severe hypersensitivity reaction. The incidence of anaphylaxis remains underestimated and there remains a low level of vigilance among all specialties, leading to underdiagnosis and consequent lack of appropriate treatment. This work is the first systematized clinical and epidemiological study performed on a cohort of patients with a history of anaphylactic reactions over 18 years of age.
AIM: To study the epidemiological features of anaphylaxis within one region of the Russian Federation, identification of its most frequent phenotypes, as well as analysis of the main errors in the management of patients with anaphylactic reactions.
MATERIALS AND METHODS: The study was conducted based on the retrospective stage analysis of data from medical records of patients with anaphylactic reactions of the Unified Medical Information and Analytical System (EMIAS) of Moscow for the period from 2019 to 2022. The final sample comprised a cohort of 241 patients.
RESULTS: In the analyzed cohort, females (n=150; 62.2%) were predominant compared to males (n=91; 37.8%). Medications (n=171; 71%) dominated the list of causative agents. The leading clinical phenotype of anaphylactic reactions in the analyzed hospitalized cohort was characterized by cardiovascular symptoms (73; 30.3%). The risks of severe course increased with age (older than 44 years) (p=0.006). Information on prehospital therapy was obtained in 183 patients (75.9%), with only 128 (70%) patients receiving epinephrine therapy. A correlation was found between the absence of epinephrine administration in the prehospital phase and the development of a biphasic course of anaphylactic reactions subsequently (p <0.001). Only 15 (38.5%) patients with an aggravated history of anaphylaxis were previously informed about the need to carry epinephrine solution.
CONCLUSIONS: Anaphylaxis is a life-threatening pathology requiring emergency medical care, regardless of the severity of the initial symptoms. Variations in the clinical symptoms that constitute the diagnostic criteria for anaphylaxis, differences in algorithms, and limitations of existing coding systems make it difficult to summarize epidemiological data and compare study results. Older age remains a risk factor for the development of severe anaphylactic reactions confirmed in our cohort.
Full Text
About the authors
Ekaterina A. Nikitina
Moscow City Hospital 52
Author for correspondence.
Email: katrin88866@gmail.com
ORCID iD: 0000-0002-0865-8355
Russian Federation, Moscow
Marina S. Lebedkina
Moscow City Hospital 52
Email: marina.ivanova0808@yandex.ru
ORCID iD: 0000-0002-9545-4720
Russian Federation, Moscow
Olga A. Mukhina
Moscow City Hospital 52
Email: mukhina.o.a@gmail.com
ORCID iD: 0000-0002-3794-4991
Russian Federation, Moscow
Sergey S. Andreev
Moscow City Hospital 52
Email: nerowolf@mail.ru
ORCID iD: 0000-0002-9147-4636
Russian Federation, Moscow
Anton A. Chernov
Moscow City Hospital 52
Email: sbornay1med@yandex.ru
ORCID iD: 0000-0001-6209-387X
MD, Cand. Sci. (Med.)
Russian Federation, MoscowNikita S. Chicunov
Moscow Center for Innovative Technologies in Healthcare
Email: artlicasio@gmail.com
ORCID iD: 0000-0002-0643-9423
Russian Federation, Moscow
Yulia M. Klimanova
The First Sechenov Moscow State Medical University (Sechenov University)
Email: klimanova_yuliya@mail.ru
ORCID iD: 0009-0009-1349-7187
MD
Russian Federation, MoscowSnezhana М. Porfireva
The First Sechenov Moscow State Medical University (Sechenov University)
Email: swetty_snejik@mail.ru
MD
Russian Federation, MoscowMariana A. Lysenko
Moscow City Hospital 52; The Russian National Research Medical University named after N.I. Pirogov
Email: gkb52@zdrav.mos.ru
ORCID iD: 0000-0001-6010-7975
MD, Dr. Sci. (Med.), Professor
Russian Federation, Moscow; MoscowDaria S. Fomina
Moscow City Hospital 52; The First Sechenov Moscow State Medical University (Sechenov University); Astana Medical University
Email: daria_fomina@mail.ru
ORCID iD: 0000-0002-5083-6637
MD, Cand. Sci. (Med.), Associate Professor
Russian Federation, Moscow; Moscow; Astana, Republic of KazakhstanReferences
- Muraro A, Agache I, Clark A, et al.; European Academy of Allergy and Clinical Immunology. EAACI food allergy and anaphylaxis guidelines: Managing patients with food allergy in the community. Allergy. 2014;69(8):1046–1057. doi: 10.1111/all.12441
- Cardona V, Ansotegui IJ, Ebisawa M, et al. World Allergy Organization anaphylaxis guidance 2020. World Allergy Organization J. 2020;13(10):100472. doi: 10.1016/j.waojou.2020.100472
- Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the nomenclature review committee of the World Allergy Organization, october 2003. J Allergy Clin Immunol. 2004;113(5):832–836. doi: 10.1016/j.jaci.2003.12.591
- Panesar SS, Javad S, de Silva D, et al.; EAACI Food Allergy and Anaphylaxis Group. The epidemiology of anaphylaxis in Europe: A systematic review. Allergy. 2013;68(11):1353–1361. doi: 10.1111/all.12272
- Hanschmann T, Francuzik W, Dölle-Bierke S, et al. Different phenotypes of drug-induced anaphylaxis--Data from the European anaphylaxis registry. Allergy. 2023;78(6):1615–1627. doi: 10.1111/all.15612
- Chaaban MR, Warren Z, Baillargeon JG, et al. Epidemiology and trends of anaphylaxis in the United States, 2004–2016. Int Forum Allergy Rhinol. 2019;9(6):607–614. doi: 10.1002/alr.22293
- Turner PJ, Gowland MH, Sharma V, et al. Increase in anaphylaxis-related hospitalizations but no increase in fatalities: An analysis of United Kingdom national anaphylaxis data, 1992–2012. J Allergy Clin Immunol. 2015;135(4):956–963.e1. doi: 10.1016/j.jaci.2014.10
- Muraro A, Worm M, Alviani C, et al.; European Academy of Allergy and Clinical Immunology, Food Allergy, Anaphylaxis Guidelines Group. EAACI guidelines: Anaphylaxis (2021 update). Allergy. 2022;77(2):357–377. doi: 10.1111/all.15032
- Clinical guidelines. Anaphylactic shock (2nd revision). Russian Association of Allergologists and Clinical Immunologists; Federation of Anaesthesiologists and Resuscitators; 2023. (In Russ). Available from: https://raaci.ru/dat/pdf/allergic_shock.pdf. Accessed: 15.01.2024.
- Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet. 1977;1(8009):466–469. doi: 10.1016/s0140-6736(77)91953-5
- Bilò MB, Martini M, Tontini C, et al. Anaphylaxis. Eur Ann Allergy Clin Immunol. 2021;53(1):4–17. doi: 10.23822/EurAnnACI.1764-1489.158
- Peavy RD, Metcalfe DD. Understanding the mechanisms of anaphylaxis. Curr Opinion Allergy Clin Immunol. 2008;8(4):310–315. doi: 10.1097/ACI.0b013e3283036a90
- Dewachter P, Mouton-Faivre C, Emala CW. Anaphylaxis and Anesthesia: Controversies and new insights. Anesthesiology. 2009;111(5):1141–1150: doi: 10.1097/ALN.0b013e3181bbd443
- Simons FE, Frew AJ, Ansotegui IJ, et al. Risk assessment in anaphylaxis: Current and future approaches. J Allergy Clin Immunol. 2007; 120(1 Suppl):S2–S24. doi: 10.1016/j.jaci.2007.05.001
- Smith PL, Kagey-Sobotka A, Bleecker ER, et al. Physiologic manifestations of human anaphylaxis. J Clin Investig. 1980;66(5):1072–1080. doi: 10.1172/JCI109936
- Khan NU, Shakeel N, Makda A, et al. Anaphylaxis: Incidence, presentation, causes and outcome in patients in a tertiary-care hospital in Karachi, Pakistan. QJM. 2013;106(12):1095–1101. doi: 10.1093/qjmed/hct179
- Wood RA, Camargo CA, Lieberman P, et al. Anaphylaxis in America: The prevalence and characteristics of anaphylaxis in the United States. J Allergy Clin Immunol. 2014;133(2):461–467. doi: 10.1016/j.jaci.2013.08.016
- Gonzalez-Estrada A, Silvers SK, Klein A, et al. Epidemiology of anaphylaxis at a tertiary care center: A report of 730 cases. Ann Allergy Asthma Immunol. 2017;118(1):80–85. doi: 10.1016/j.anai.2016.10.025
- Liew WK, Chiang WC, Goh AE, et al. Paediatric anaphylaxis in a Singaporean children cohort: Changing food allergy triggers over time. Asia Pac Allergy. 2013;3(1):29–34. doi: 10.5415/apallergy.2013.3.1.29
- Worm M, Moneret-Vautrin A, Scherer K, et al. First European data from the network of severe allergic reactions (NORA). Allergy. 2014;69(10):1397–1404. doi: 10.1111/all.12475
- Aun MV, Blanca M, Garro LS, et al. Nonsteroidal anti-inflammatory drugs are major causes of drug-induced anaphylaxis. J Allergy Clin Immunol Pract. 2014;2(4):414–420. doi: 10.1016/j.jaip.2014.03.014
- Poziomkowska-Gęsicka I, Kurek M. Clinical manifestations and causes of anaphylaxis. Analysis of 382 Cases from the Anaphylaxis Registry in West Pomerania Province in Poland. Int J Environ Res Public Health. 2020;17(8):2787. doi: 10.3390/ijerph17082787
- Peng MM, Jick H. A population-based study of the incidence, cause and severity of anaphylaxis in the United Kingdom. Arch Intern Med. 2004;164(3):317–319. doi: 10.1001/archinte.164.3.317
- Jarez EJ, Cagnani CE, Sanches-Borges M, et al. Drug induced anaphylaxis in Latin American countries. J Allergy Clin Immunol Pract. 2015;3(5):780–788. doi: 10.1016/j.jaip.2015.05.012
- Doña I, Pérez-Sánchez N, Eguiluz-Gracia I, et al. Progress in understanding hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Allergy. 2020;75(3):561–575. doi: 10.1111/all.14032
- Himly M, Jahn-Schmid B, Pittertschatscher K, et al. IgE-mediated immediate-type hypersensitivity to the pyrazolone drug propyphenazone. J Allergy Clin Immunol. 2003;111(4):882–888. doi: 10.1067/mai.2003.163
- Torres MJ, Montanez MI, Ariza A, et al. The role of IgE recognition in allergic reactions to amoxicillin and clavulanic acid. Clin Exp Allergy. 2016;46(2):264–274. doi: 10.1111/cea.12689
- Bogas G, Mayorga C, Martín-Serrano Á, et al. Penicillin and cephalosporin cross-reactivity: Role of side chain and synthetic cefadroxil epitopes. Clin Transl Allergy. 2020;10(1):57. doi: 10.1186/s13601-020-00368-1
- Brazil E, MacNamara AF. "Not so immediate" hypersensitivity--the danger of biphasic anaphylactic reactions. J Accid Emergency Med. 1998;15(4):252–253. doi: 10.1136/emj.15.4.252
- Douglas DM, Sukenick E, Andrade WP, Brown JS. Biphasic systemic anaphylaxis: An inpatient and outpatient study. J Allergy Clin Immunol. 1994;93(6):977–985. doi: 10.1016/s0091-6749(94)70044-3
- Stark BJ, Sullivan TJ. Biphasic and protracted anaphylaxis. J Allergy Clin Immunol. 1986;78(1 Pt 1):76–83. doi: 10.1016/0091-6749(86)90117-x
- Confino-Cohen R, Goldberg A. Allergen immunotherapy-induced biphasic systemic reactions: incidence, characteristics, and outcome: A prospective study. Ann Allergy Asthma Immunol. 2010;104(1):73–78. doi: 10.1016/j.anai.2009.11.001
- Liu X, Lee S, Lohse CM, et al. Biphasic reactions in emergency department anaphylaxis patients: A prospective cohort study. J Allergy Clin Immunol Pract. 2020;8(4):1230–1238. doi: 10.1016/j.jaip.2019.10.027
- Kemp SF, Lockey RF. Anaphylaxis: A review of causes and mechanisms. J Allergy Clin Immunol. 2002;110(3):341–348. doi: 10.1067/mai.2002.126811
- Worm M, Francuzik W, Renaudin JM, et al. Factors increasing the risk for a severe reaction in anaphylaxis: An analysis of data from the European Anaphylaxis Registry. Allergy. 2018;73(6):1322–1330. doi: 10.1111/all.13380
- Francuzik W, Kraft M, Scherer Hofmeier K, et al. Anaphylaxis in middle-aged patients. Allergol Select. 2021;(5):133–139. doi: 10.5414/ALX02216E
- Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med. 1992;327(6):380–384. doi: 10.1056/NEJM199208063270603
- Francuzik W, Nassiri M, Babina M, Worm M. Impact of sex on anaphylaxis severity--data from the Anaphylaxis Registry. J Allergy Clin Immunol. 2015;136(5):1425–1426. doi: 10.1016/j.jaci.2015.06.052
- Lieberman P, Camargo CA, Bohlke K, et al. Epidemiology of anaphylaxis: Findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group. Ann Allergy Asthma Immunol. 2006;97(5):596–602. doi: 10.1016/S1081-1206(10)61086-1
- Van der Klauw MM, Wilson JH, Stricker BH. Drug-associated anaphylaxis: 20 years of reporting in The Netherlands (1974–1994) and review of the literature. Clin Exp Allergy. 1996;26(12):1355–1363. doi: 10.1046/j.1365-2222.1996.d01-300
- Simons FE, Gu X, Johnston LM, Simons KJ. Can epinephrine inhalations be substituted for epinephrine injection in children at risk for systemic anaphylaxis? Pediatrics. 2000;106(5):1040–1044. doi: 10.1542/peds.106.5.1040
- Grabenhenrich LB, Dölle S, Ruëff F, et al. Epinephrine in severe allergic reactions: The European anaphylaxis register. J Allergy Clin Immunol Pract. 2018;6(6):1898–1906.e1. doi: 10.1016/j.jaip.2018.02.026
- Vitte J, Amadei L, Gouitaa M, et al. Paired acute-baseline serum tryptase levels in perioperative anaphylaxis: An observational study. Allergy. 2019;74(6):1157–1165. doi: 10.1111/all.13752
- Lyons JJ, Yu X, Hughes JD, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nature Genetics. 2016;48(12):1564–1569. doi: 10.1038/ng.3696
- Valent P, Akin C. Doctor, I Think I. Am suffering from MCAS: Differential diagnosis and separating facts from fiction. J Allergy Clin Immunol. 2019;7(4):1109–1114. doi: 10.1016/j.jaip.2018.11.045